This narrative review evaluates the efficacy and safety of transcranial magnetic stimulation for treating Alzheimer's disease, suggesting future research directions.
Alzheimer’s disease (AD) is the most common neurodegenerative disease that accounts for 60–80% of all dementia cases and affects millions of people worldwide. At present, standard drug therapies provide only limited symptomatic relief. Therefore, the exploration of novel therapeutic approaches is crucial for improving patient outcomes. Transcranial magnetic stimulation (TMS) has emerged as a promising non-invasive neuromodulation technique that may provide benefit in AD management. This review discusses the pathophysiological mechanisms by which TMS operates, evaluates its clinical efficacy in AD patients, assesses its safety profile, and suggests future directions for research.
No takes yet. Share an insight, caveat, or question.
Papaliagkas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: